SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001558370-24-000770
Filing Date
2024-02-05
Accepted
2024-02-05 16:31:05
Documents
14
Period of Report
2024-01-15
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K/A acrs-20240115x8ka.htm   iXBRL 8-K/A 44875
  Complete submission text file 0001558370-24-000770.txt   166418

Data Files

Seq Description Document Type Size
2 EX-101.SCH acrs-20240115.xsd EX-101.SCH 3133
3 EX-101.LAB acrs-20240115_lab.xml EX-101.LAB 15914
4 EX-101.PRE acrs-20240115_pre.xml EX-101.PRE 10221
15 EXTRACTED XBRL INSTANCE DOCUMENT acrs-20240115x8ka_htm.xml XML 4842
Mailing Address 701 LEE ROAD SUITE 103 WAYNE PA 19087
Business Address 701 LEE ROAD SUITE 103 WAYNE PA 19087 484-324-7933
Aclaris Therapeutics, Inc. (Filer) CIK: 0001557746 (see all company filings)

IRS No.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-37581 | Film No.: 24596164
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)